Skip to main content
Clinical Trials/ITMCTR2000003109
ITMCTR2000003109Not yet recruitingPhase 4

Clinical study of Weierkang pills combined with triple therapy for Helicobacter pylori infection

Department of Gastroenterology, Run Run Shaw Hospital of Zhejiang University School of Medicine0 sitesStarted: TBDLast updated:

Trial Snapshot

Phase
Phase 4
Status
Not yet recruiting
Sponsor

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional study

Eligibility Criteria

Ages
18 to 90 (—)
Sex
All

Inclusion Criteria

  • 1. Voluntarily sign the informed consent;
  • 2. The age is more than 18 years old, men and women are not limited;
  • 3. Patients who were Hp positive without anti-bacterial treatment;

Exclusion Criteria

  • 1. Patients who have used antibiotics or bismuth agent within 4 weeks; Patients who had used antacids (H2 antagonists or proton pump inhibitors), prokinetic drugs (mosapride or doperidone, etc.) and gastric mucosa protectants (tipredone, sucralose, rabapet, etc.) in the previous 2 weeks;
  • 2. Patients with serious lesions in important organs of the body (heart, liver, kidney, lung, etc.);
  • 3. Patients diagnosed with gastric cancer by gastroscopy or other examinations;
  • 4. Pregnant and nursing women;
  • 5. Unable to follow visitors or allergic to this study.

Investigators

Sponsor
Department of Gastroenterology, Run Run Shaw Hospital of Zhejiang University School of Medicine

Similar Trials

Clinical study of Weierkang pills combined... | Clinical Trial